Communiqués Eledon Pharmaceuticals, Inc.

Actions

ELDN

US28617K1016

Temps Différé Nasdaq Autres places de cotation 19:56:25 17/07/2024			Varia. 5j.	Varia. 1 janv.
2,72 ^USD	-3,89 %		+11,93 %	+51,11 %

03/06	Eledon Pharmaceuticals, Inc. Eledon Pharmaceuticals Inc. présente les données actualisées de l'étude de phase 1B en cours évaluant le tegoprubart pour la prévention du rejet dans le cadre de la transplantation rénale	CI
13/05	Eledon Pharmaceuticals, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Eledon Pharmaceuticals : Submission of Matters to a Vote of Security Holders Form 8 K	10/07	PU
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism	02/07	GL
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	03/06	GL
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results	09/05	GL
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress	09/05	GL
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection	07/05	GL
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement	07/05	GL
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results	28/03	GL
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection	25/03	GL
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human	21/03	GL
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human	21/03	AQ
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	14/02	GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	14/02	AQ
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook	04/01	GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/12	GL
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/12	AQ
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference	29/11	GL
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results	09/11	GL
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference	08/11	GL
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	02/11	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Eledon Pharmaceuticals, Inc.

Actions

ELDN

US28617K1016

Communiqués

Filtres